MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, announced that the first patients have been dosed in a Phase II clinical trial of its lead drug candidate Pracinostat in combination with Vidaza (azacitidine) in patients with previously Result

read more>>

A genetically reprogrammed Herpes simplex virus can cure metastatic diffusion of human cancer cells in the abdomen of laboratory mice, according to a new study published January 31 in the Open Access journal PLOS PathogensThe paper reports on the collaborative research from scientists at the at th

read more>>

A new approach to reducing sickle cell anemia's painful attacks has entered Phase II clinical trialsThe drug, Lexiscan, is already approved for diagnosing heart disease. Scientists led by Joel Linden, a researcher at the La Jolla Institute for Allergy & Immunology, discovered that the drug might a

read more>>

Hyperion Therapeutics, Inc. announced that population pharmacokinetic (PK) modeling and dosing simulations were reported in The Journal of Clinical Pharmacology based on data from four Phase 2 and 3 trials that collectively enrolled patients with urea cycle disorders (UCDs) ages 2 months to 72 UCD

read more>>

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of marketing, commercial strategy, and operations. Mr. Northcott brings extensive commercial

read more>>

Roche announced that the Japanese Ministry of Health, Labour and Welfare has approved Avastin for the treatment of malignant glioma, including newly diagnosed glioblastoma in combination with radiotherapy and temozolomide chemotherapy, and as monotherapy for treatment of recurrent GBM and certain

read more>>

AbbVie announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).

read more>>

Desiccated thyroid extract (DTE), derived from crushed preparations of animal thyroid glands, is a safe and effective alternative to standard T4 therapy in hypothyroid patients, a new study finds. The results will be presented at The Endocrine Society's 95th Annual Meeting in San FranciscoIn adult

read more>>

Santarus, Inc. and Pharming Group NV announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Biologics License Application (BLA) for the investigational drug RUCONEST® (recombinant human C1 esterase inhibitor) 50 IU/kg. Santarus and Pharming are seeking U.S. marketin

read more>>

Vanda Pharmaceuticals Inc. presented additional data at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. This effect further confirms tasimelteon's potential to reset the master body clock and The

read more>>